Century Therapeutics
(NASDAQ:IPSC)
$3.13
0[0.00%]
At close: Apr 23
$3.13
0[0.00%]
PreMarket: 4:02PM EDT
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Century Therapeutics Stock (NASDAQ:IPSC), Quotes and News Summary

Century Therapeutics Stock (NASDAQ: IPSC) stock price, news, charts, stock research, profile.

Open-
Close-
Volume / Avg.0 / 213.405K
Day Range- - -
52 Wk Range1.280 - 5.510
Market Cap$202.880M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
38
Short Interest
7.23%
Days to Cover12.67

Recent News

Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.
Vandana Singh
Sponsored
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps & Tech-heavy QQQ ETF by 11.4% (MTD)
Piero Cingari
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Dec 23
2
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Century Therapeutics Inc
Sector
Health Care
Industry
Biotechnology
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to de...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
IPSC
ZURA

FAQ

Q

How do I buy Century Therapeutics (IPSC) stock?

A

You can purchase shares of Century Therapeutics (NASDAQ: IPSC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Century Therapeutics's (IPSC) competitors?

A

Other companies in Century Therapeutics’s space includes: Zura Bio (NASDAQ:ZURA), Outlook Therapeutics (NASDAQ:OTLK), Innate Pharma (NASDAQ:IPHA), Galectin Therapeutics (NASDAQ:GALT) and bluebird bio (NASDAQ:BLUE).

Q

What is the target price for Century Therapeutics (IPSC) stock?

A

The latest price target for Century Therapeutics (NASDAQ: IPSC) was reported by Piper Sandler on Friday, April 12, 2024. The analyst firm set a price target for 9.00 expecting IPSC to rise to within 12 months (a possible 187.54% upside). 10 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Century Therapeutics (IPSC)?

A

The stock price for Century Therapeutics (NASDAQ: IPSC) is $3.13 last updated April 23, 2024 at 4:02 PM EDT.

Q

Does Century Therapeutics (IPSC) pay a dividend?

A

There are no upcoming dividends for Century Therapeutics.

Q

When is Century Therapeutics (NASDAQ:IPSC) reporting earnings?

A

Century Therapeutics’s Q1 earnings are confirmed for Thursday, May 9, 2024.

Q

Is Century Therapeutics (IPSC) going to split?

A

There is no upcoming split for Century Therapeutics.

Q

What sector and industry does Century Therapeutics (IPSC) operate in?

A

Century Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch